who medicines strategy - libdoc.who.int - World Health Organization
who medicines strategy - libdoc.who.int - World Health Organization who medicines strategy - libdoc.who.int - World Health Organization
WHO MEDICINES STRATEGY 2004-2007 | 114EO 7.1Rational use of medicines byhealth professionals and consumersadvocatedRationaleDecisions about the use of medicines arestrongly influenced by health professionalsand consumers. However, it is these twogroups which can be the most reluctant toimplement policies about rational use. Forhealth professionals and prescribers, rationaluse will often conflict with peer pressure and/orcommercial interests. For consumers, especiallywhere the treatment is free of charge or in theevent of serious illness, there is a natural demandto have the ‘latest’ treatment (on the assumptionthat this equates to ‘best’) regardless of cost. Bothof these groups are influenced by the marketingand promotional activities of product patentholders. Despite the scientific logic of rationaluse training and guidance material, such astreatment protocols, there is strong resistance totheir application.ProgressThere has been a major increase in the volumeof information in support of rational use, togetherwith increasing use of objective scientificevidence to formulate protocols and policiesat international and country levels. The rapidexpansion of movements such as the CochraneFoundation has made vital information readilyavailable. WHO has contributed to this processover the past 20 years through demonstratingthe value of evidence-based action. The EssentialDrug Monitor, a twice-yearly publication witha 40 000 print-run issued in five languages, isa major channel for advocacy among healthprofessionals and policy-makers. Some of thethemes covered have included prescribing skills,improving drug use, drug donations, networkingfor action, managing drug supply, access,antimicrobial resistance, medicines promotion,and 25 years of the essential medicines concept.Other networks concerned with promotingrational use of medicines have also beensupported, including INRUD, INDIA-DRUG (anemail discussion group) and the InternationalSociety for Drug Bulletins. In 2003, in response tothe increasing problem of patient failure to adhereto therapy for chronic diseases, WHO published areview of the evidence for action. 57Challenges remainingThere is a need to engage some of the majorplayers — manufacturers, prescribers, andproviders and consumers of medicines — onthe importance of ensuring the rational use ofmedicines. The challenge is to find ways andmeans to translate the logic of the existing rationaluse messages and practice into convinced actionby the majority of practitioners and consumers.Although intervention research during the pastdecade has helped identify strategies andinterventions that are effective in promotingrational use of medicines, many of these strategieshave not been taken on board by governments.In many countries today, more than half of allpatients are not treated in accordance withclinical guidelines (WHO/EDM rational drug usedatabase, 2003).
COMPONENTS OF THE STRATEGY | 115Meeting the challenges 2004-2007Over the next four years WHO will:> adapt and distribute materials to countries andpromote the use of training and networkingwith consumer groups and professionalsocieties. While some activities willstrengthen the existing training courses, otherswill involve the more effective use of theInternet to disseminate information.> broaden the scope of rational use activitiesto include chronic diseases such as HIV/AIDS, particularly on the issue of treatmentadherence.> launch a coordinated plan of activity atcountry, regional, and headquarter levels, toensure that participants in all training coursesare followed up more closely at country level.> conduct a readership survey and evaluationof the Essential Drugs Monitor and makechanges where necessary to increasecirculation.OUTCOME INDICATORS1999 2003 2007No. of countries where the promotion of the rational use ofmedicines is coordinated at the national government level#REPORTING % TARGET#REPORTING % TARGETna na na 93/127 73% 75%
- Page 76 and 77: WHO MEDICINES STRATEGY 2004-2007 |
- Page 78 and 79: WHO MEDICINES STRATEGY 2004-2007 |
- Page 80 and 81: WHO MEDICINES STRATEGY 2004-2007 |
- Page 82 and 83: WHO MEDICINES STRATEGY 2004-2007 |
- Page 84 and 85: WHO MEDICINES STRATEGY 2004-2007 |
- Page 86 and 87: WHO MEDICINES STRATEGY 2004-2007 |
- Page 88 and 89: WHO MEDICINES STRATEGY 2004-2007 |
- Page 90 and 91: WHO MEDICINES STRATEGY 2004-2007 |
- Page 92 and 93: WHO MEDICINES STRATEGY 2004-2007 |
- Page 94 and 95: WHO MEDICINES STRATEGY 2004-2007 |
- Page 96 and 97: WHO MEDICINES STRATEGY 2004-2007 |
- Page 98 and 99: WHO MEDICINES STRATEGY 2004-2007 |
- Page 100 and 101: WHO MEDICINES STRATEGY 2004-2007 |
- Page 102 and 103: WHO MEDICINES STRATEGY 2004-2007 |
- Page 104 and 105: WHO MEDICINES STRATEGY 2004-2007 |
- Page 106 and 107: WHO MEDICINES STRATEGY 2004-2007 |
- Page 108 and 109: WHO MEDICINES STRATEGY 2004-2007 |
- Page 110 and 111: WHO MEDICINES STRATEGY 2004-2007 |
- Page 112 and 113: WHO MEDICINES STRATEGY 2004-2007 |
- Page 114 and 115: WHO MEDICINES STRATEGY 2004-2007 |
- Page 116 and 117: WHO MEDICINES STRATEGY 2004-2007 |
- Page 118 and 119: WHO MEDICINES STRATEGY 2004-2007 |
- Page 120 and 121: WHO MEDICINES STRATEGY 2004-2007 |
- Page 122 and 123: WHO MEDICINES STRATEGY 2004-2007 |
- Page 124 and 125: WHO MEDICINES STRATEGY 2004-2007 |
- Page 128 and 129: WHO MEDICINES STRATEGY 2004-2007 |
- Page 130 and 131: WHO MEDICINES STRATEGY 2004-2007 |
- Page 132 and 133: WHO MEDICINES STRATEGY 2004-2007 |
- Page 134 and 135: WHO MEDICINES STRATEGY 2004-2007 |
- Page 136 and 137: WHO MEDICINES STRATEGY 2004-2007 |
- Page 138 and 139: WHO MEDICINES STRATEGY 2004-2007 |
- Page 140 and 141: WHO MEDICINES STRATEGY 2004-2007 |
- Page 142 and 143: WHO MEDICINES STRATEGY 2004-2007 |
- Page 144 and 145: WHO MEDICINES STRATEGY 2004-2007 |
- Page 146 and 147: WHO MEDICINES STRATEGY 2004-2007 |
- Page 148 and 149: WHO MEDICINES STRATEGY 2004-2007 |
- Page 150 and 151: WHO MEDICINES STRATEGY 2004-2007 |
- Page 152 and 153: WHO MEDICINES STRATEGY 2004-2007 |
- Page 154 and 155: WHO MEDICINES STRATEGY 2004-2007 |
- Page 157 and 158: REFERENCES
- Page 159 and 160: REFERENCES | 1471Annual report 2000
- Page 161 and 162: REFERENCES | 14912 th Model List of
COMPONENTS OF THE STRATEGY | 115Meeting the challenges 2004-2007Over the next four years WHO will:> adapt and distribute materials to countries andpromote the use of training and networkingwith consumer groups and professionalsocieties. While some activities willstrengthen the existing training courses, otherswill involve the more effective use of theInternet to disseminate information.> broaden the scope of rational use activitiesto include chronic diseases such as HIV/AIDS, particularly on the issue of treatmentadherence.> launch a coordinated plan of activity atcountry, regional, and headquarter levels, toensure that participants in all training coursesare followed up more closely at country level.> conduct a readership survey and evaluationof the Essential Drugs Monitor and makechanges where necessary to increasecirculation.OUTCOME INDICATORS1999 2003 2007No. of countries where the promotion of the rational use of<strong>medicines</strong> is coordinated at the national government level#REPORTING % TARGET#REPORTING % TARGETna na na 93/127 73% 75%
Change language